Month: July 2026

WATERTOWN, Mass., July 30, 2026 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today reported financial results for the second quarter ended June 30, 2026, and provided a review… … […]

CAMBRIDGE, Mass., July 30, 2026 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that the company will host a conference call on August 6, 2026,… … […]

MARLBOROUGH, Mass.–(BUSINESS WIRE)–Sumitomo Pharma America, Inc. (SMPA) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to enzomenib (DSP-5336) for the treatment of patients with acute lymphoblastic leukemia (ALL). Enzomenib is an investigational, oral, small molecule inhibitor of the menin and lysine (K)-specific methyltransferase… … […]

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2026, and reviewed recent business highlights. “During the first half of 2026, we continued to meaningfully advance our business, generating over $1 billion in quarterly… … […]

CAMBRIDGE, Mass., July 30, 2026 (GLOBE NEWSWIRE) — Atavistik Bio, a clinical-stage biotechnology company developing the next generation of oral selective allosteric therapeutics for the treatment of rare hematological diseases, today announced it has joined the Cure HHT Clinical Trial Network (CTN) to support the clinical development of ATV-1601, an… … […]

Clinically studied Schedule 8 cannabinoid sleep capsule now available to Australian patients by prescription through TGA-authorized medical channels. PEABODY, Mass., July 28, 2026 /PRNewswire-PRWeb/ — Sanna Science, a Massachusetts-based research-driven company focused on developing safe… … […]

CAMBRIDGE, Mass.–(BUSINESS WIRE)– #InVivoCART–Sail Biomedicines Announces Strategic Collaboration to Develop New Class of Medicines for In Vivo CAR-T … […]

A GWAS meta-analysis including 2.5 million individuals identified 26 genetic risk factors linked with fibromyalgia, identifying risk variants in 26 regions of the genome, many which are involved in brain and nerve function. The post Genetic Study of Fibromyalgia Points to Neurological Basis appeared first on GEN… … […]